Unfortunately, in the context of EAE/MS, there was little direct evidence for a distinct modulatory effect of Treg cell-derived IL-10/TGF-β/IL-35 on DC maturation and antigen presentation ability. The gene discussed is TGFB1; the disease is myeloid sarcoma.